Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
237 results:
1. Obesity enhances the response to neoadjuvant anti-pd1 therapy in oral tongue squamous cell carcinoma.
Tan X; Li G; Deng H; Xiao G; Wang Y; Zhang C; Chen Y
Cancer Med; 2024 Jun; 13(12):e7346. PubMed ID: 38923758
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
[TBL] [Abstract] [Full Text] [Related]
3. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
Tsukada Y; Bando H; Inamori K; Wakabayashi M; Togashi Y; Koyama S; Kotani D; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Sato A; Nishikawa H; Ito M; Yoshino T
Br J Cancer; 2024 Jul; 131(2):283-289. PubMed ID: 38834744
[TBL] [Abstract] [Full Text] [Related]
4. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis.
Tang W; Li C; Huang D; Zhou S; Zheng H; Wang Q; Zhang X; Fu J
Cancer Biol Ther; 2024 Dec; 25(1):2358551. PubMed ID: 38813753
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies.
Ziane Bouziane S; Mans L; Bucalau AM; Demetter P; Pezzullo M; Andre C; Loi P; Navez J; Marcelis L; Puleo F; Charette N; Closset J; Van Laethem JL
Eur J Cancer; 2024 Jul; 206():114128. PubMed ID: 38805957
[TBL] [Abstract] [Full Text] [Related]
6. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract] [Full Text] [Related]
7. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
8. Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.
Hao L; Lu W; Wu J; Chen Y; Xu D; Wang P
Sci Rep; 2024 Apr; 14(1):8983. PubMed ID: 38637684
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
[TBL] [Abstract] [Full Text] [Related]
10. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
[TBL] [Abstract] [Full Text] [Related]
11. Exploring the clinical significance of IL-38 correlation with pd-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
[TBL] [Abstract] [Full Text] [Related]
12. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
[TBL] [Abstract] [Full Text] [Related]
13. Intratumoral injection of interferon gamma promotes the efficacy of anti-pd1 treatment in colorectal cancer.
Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
[TBL] [Abstract] [Full Text] [Related]
14. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
[TBL] [Abstract] [Full Text] [Related]
15. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-pd-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract] [Full Text] [Related]
16. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
He R; Huang S; Lu J; Su L; Gao X; Chi H
Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
[TBL] [Abstract] [Full Text] [Related]
17. Immune cell infiltrates in peritoneal metastases from colorectal cancer.
Sundström P; Hogg S; Quiding Järbrink M; Bexe Lindskog E
Front Immunol; 2024; 15():1347900. PubMed ID: 38384469
[TBL] [Abstract] [Full Text] [Related]
18. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract] [Full Text] [Related]
19. Interferon Gamma Induces Higher Neutrophil Extracellular Traps Leading to Tumor-Killing Activity in Microsatellite Stable colorectal cancer.
Teng HW; Wang TY; Lin CC; Tong ZJ; Cheng HW; Wang HT
Mol Cancer Ther; 2024 Jul; 23(7):1043-1056. PubMed ID: 38346939
[TBL] [Abstract] [Full Text] [Related]
20. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
[Next]
